Search Results - "Barnes, Gisoo"

Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma by Serrano, Daniel, Podger, Lauren, Barnes, Gisoo, Song, James, Tang, Boxiong

“…To demonstrate the measurement properties of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Hepatocellular…”
Get full text

G‐CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use by Barnes, Gisoo, Pathak, Ashutosh, Schwartzberg, Lee

“…Febrile neutropenia (FN) is a common complication among patients with chemotherapy‐induced myelotoxicity and is associated with a number of negative outcomes…”
Get full text

The effects of tislelizumab treatment on the health‐related quality of life of patients with advanced non‐small cell lung cancer by Huang, Dingzhi, Zhou, Caicun, Barnes, Gisoo, Ma, Yiyuan, Li, Songzi, Zhan, Lin, Tang, Boxiong

“…This study examined the health‐related quality of life (HRQoL) of patients with advanced non‐small cell lung cancer (NSCLC) receiving tislelizumab versus…”
Get full text

Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States by Veluswamy, Rajwanth, Hirsch, Fred R., Taioli, Emanuela, Wisnivesky, Juan, Strauss, Ross, Harrough, Douglas, Tang, Boxiong, Barnes, Gisoo

“…Background Immune checkpoint inhibitors targeting the programmed cell death protein‐1 (PD‐1) and programmed death ligand‐1 (PD‐L1) axis (collectively referred…”
Get full text

P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH‐RELATED QUALITY OF LIFE (HRQOL) by Eichhorst, Barbara, Lamanna, Nicole, O’brien, Susan, Tam, Constantine, Qiu, Lugui, Yang, Keri, Wu, Ken, Salmi, Tommi, Barnes, Gisoo, Brown, Jennifer R.

Get full text

Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective by Kruse, Morgan, Wildner, Rebecca, Barnes, Gisoo, Martin, Monique, Mueller, Udo, Lo-Coco, Francesco, Pathak, Ashutosh

“…The objective of this study was to estimate the net cost of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) compared to ATRA plus chemotherapy…”
Get full text

P1679: HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN TRIAL LONG‐TERM FOLLOW‐UP by Tedeschi, Alessandra, Tam, Constantine, Owen, Roger, Buske, Christian, Leblond, Véronique, Dimopoulos, Meletios A., García‐Sanz, Ramón, Castillo, Jorge, Trotman, Judith, Treon, Steven, Yang, Keri, Tang, Boxiong, Allewelt, Heather, Patel, Sheel, Chan, Wai, Cohen, Aileen, Schneider, Jingjing Yan, Barnes, Gisoo

Get full text

Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life by Korde, Rasika, Veluswamy, Rajwanth, Allaire, Jason C., Barnes, Gisoo

“…This systematic literature review examines the current immune checkpoint inhibitors treatment paradigms, treatment gaps and unmet needs for treating SCLC with…”
Get full text

The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen by Zhou, Cai, Huang, Dingzhi, Ma, Yiyuan, Pan, Zhenyu, Barnes, Gisoo, Tang, Boxiong

“…Abstract only 9069 Background: Anti-PD-1/L1 therapies have improved overall survival (OS) by 2-4 months vs docetaxel in patients with advanced non−small cell…”
Get full text

Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer by Lu, Shun, Yu, Yan, Barnes, Gisoo, Qiu, Xiusong, Bao, Yuanyuan, Tang, Boxiong

“…This study assessed the effects of tislelizumab, a programmed cell death protein 1 inhibitor, in combination with chemotherapy versus chemotherapy alone as…”
Get full text

Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial by Trotman, Judith, Zinzani, Pier Luigi, Song, Yuqin, Delarue, Richard, Barnes, Gisoo, Kim, Pil, Ivanova, Elena, Tang, Boxiong, Mayer, Jiří, De Oliveira, Ana C., Assouline, Sarit, Flowers, Christopher R.

“…Introduction: Zanubrutinib is a potent and highly selective next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and…”
Get full text

Effects of tislelizumab on health‐related quality of life in patients with recurrent or metastatic nasopharyngeal cancer by Yang, Yunpeng, Pan, Jianji, Chen, Nianyong, Guo, Ye, Huang, Xiaoming, Wu, Yanjie, Leaw, Shiangjiin, Bai, Fan, Wang, Yu, Zhao, Na, Tang, Boxiong, Barnes, Gisoo

“…Background This study evaluated health‐related quality of life (HRQoL) in the RATIONALE‐309 (NCT03924986) intent‐to‐treat (ITT) population and in a subgroup of…”
Get full text

MO19-4 Impact of tislelizumab on health-related quality of life in Asian patients with esophageal squamous cell carcinoma by Kato, Ken, Van Cutsem, Eric, Ajani, Jaffer, Shen, Lin, Barnes, Gisoo, Ding, Ningning, Tao, Aiyang, Xia, Tianyu, Zhan, Lin, Kim, Sung-Bae

Get full text

Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population by Finn, Richard S., Qin, Shukui, Kudo, Masatoshi, Meyer, Tim, Boisserie, Frederic, Li, Songzi, Chen, Yaxi, Barnes, Gisoo, Abdrashitov, Ramil, Zhu, Andrew X., Vogel, Arndt

“…495 Background: RATIONALE-301 (NCT03412773), a global Phase 3 study, comparing tislelizumab (TIS) to sorafenib (SOR) as 1L treatment in adult patients (pts)…”
Get full text

Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients by Kim, Sung-Bae, Van Cutsem, Eric, Ajani, Jaffer, Shen, Lin, Barnes, Gisoo, Ding, Ningning, Tao, Aiyang, Xia, Tianyu, Zhan, Lin, Kato, Ken

“…Post-hoc analysis examined health-related quality of life and esophageal squamous cell carcinoma (ESCC) symptoms in the Asian subgroup of patients in…”
Get full text

Use of PD-1 and PD-L1 inhibitors after first-line therapy in esophageal cancer patients in the US by Allaire, Jason C., Balk, Mark, Azmi, Soraya, Handl, Heather L., Yang, Keri, Barnes, Gisoo

“…Esophageal cancer (EC) makes up 3.2% of all cancers but ranks sixth among cancer-related deaths worldwide. This real-world analysis determined the use of…”
Get full text

Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL) by Van Cutsem, Eric, Kato, Ken, Ajani, Jaffer A., Shen, Lin, Xia, Tianyu, Ding, Ningning, Zhan, Lin, Barnes, Gisoo, Kim, Sung-Bae

“…e16095 Background: RATIONALE 302 was a global phase 3 study (NCT03430843) that investigated tislelizumab (TIS) compared with investigator-chosen chemotherapy…”
Get full text

Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL) by Van Cutsem, Eric, Kato, Ken, Ajani, Jaffer A., Shen, Lin, Xia, Tianyu, Ding, Ningning, Zhan, Lin, Barnes, Gisoo, Kim, Sung-Bae

“…Abstract only 268 Background: RATIONALE 302 was a global phase 3 study (NCT03430843) that investigated tislelizumab (TIS) compared with investigator-chosen…”
Get full text

Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial by Trotman, Judith, Zinzani, Pier Luigi, Song, Yuqin, Delarue, Richard, Kim, Pil, Ivanova, Elena, Korde, Rasika, Mayer, Jiří, De Oliveira, Ana C, Assouline, Sarit E, Flowers, Christopher R, Barnes, Gisoo

“…We report patient-reported outcomes (PROs) measuring health-related quality of life (HRQoL) from the ROSEWOOD trial (NCT03332017), which demonstrated superior…”
Get full text

Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial by Tam, Constantine S, Lamanna, Nicole, O'Brien, Susan M, Qiu, Lugui, Yang, Keri, Barnes, Gisoo, Wu, Ken, Salmi, Tommi, Brown, Jennifer R

“…The purpose of this analysis was to assess health-related quality of life (HRQoL) in patients treated with zanubrutinib and ibrutinib in the ALPINE trial…”
Get full text